Compass Therapeutics (NASDAQ:CMPX) Cut to Market Perform at Leerink Partners

Leerink Partners lowered shares of Compass Therapeutics (NASDAQ:CMPX) from an outperform rating to a market perform rating in a research report released on Friday, Marketbeat.com reports. The firm currently has $4.00 price target on the stock, down from their prior price target of $5.00.

Several other research analysts have also issued reports on CMPX. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a research note on Monday, September 16th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research report on Monday, November 11th. Finally, Wedbush restated an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.75.

Compass Therapeutics Trading Down 13.2 %

Shares of Compass Therapeutics stock opened at $1.38 on Friday. The business has a 50-day moving average price of $1.75 and a two-hundred day moving average price of $1.42. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.34. The company has a market cap of $189.87 million, a P/E ratio of -3.73 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. Equities research analysts forecast that Compass Therapeutics will post -0.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Rovin Capital UT ADV acquired a new position in shares of Compass Therapeutics during the third quarter valued at about $25,000. Intech Investment Management LLC bought a new stake in Compass Therapeutics during the 3rd quarter worth approximately $30,000. XTX Topco Ltd bought a new stake in Compass Therapeutics during the 3rd quarter worth approximately $37,000. Cubist Systematic Strategies LLC bought a new stake in Compass Therapeutics during the 2nd quarter worth approximately $41,000. Finally, Panagora Asset Management Inc. purchased a new stake in shares of Compass Therapeutics in the second quarter worth approximately $68,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.